Study Title and Description
Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women.
Key Questions Addressed
|3||Key Question 3. What are the harms of using medications to reduce risk for primary breast cancer? Key Question 3a. Do harms of risk-reducing medications vary by timing of initiation and/or duration of use? Key Question 3b. Do harms of risk-reducing medications persist beyond discontinuation of use?|
Primary Publication Information
|Title||Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women.|
|Author||Nickelsen T., Lufkin EG., Riggs BL., Cox DA., Crook TH.|
|Country||Lilly Deutschland GmbH, Bad Homburg, Germany.|
Pubmed ID: 10098223
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Questions 1-4
Results & Comparisons
No Results found.